Cipla Products List: Owner, Cipla NSE Share Price [2023]

Profile of Cipla Pharma Inc. and Cipla Products List and share price, List of Cipla subsidiaries along with the owner, awards, and history. Cipla’s mission is to make quality medicines affordable to all, with a focus on ensuring access to essential medicines in developing countries and overall growing the pharma industry of India.

Cipla is a leading global pharmaceutical company, with a presence in over 170 countries. Cipla manufactures and supplies a wide range of medicines, including those for infectious diseases, respiratory disorders, cardiovascular diseases, diabetes, and cancer.

Company Overview: Cipla Owner

Cipla is a global pharmaceutical company with a presence in over 170 countries. It is headquartered in Mumbai, India, and has over 30,000 employees. Cipla is the third-largest pharmaceutical company in India by revenue. The company was founded in 1935 by Dr. K.A. Hamied and today is one of the world’s leading producers of generic drugs.

Cipla’s product portfolio includes over 1,500 molecules across various therapeutic areas including anti-infectives, cardiovascular, diabetology, respiratory, oncology, and central nervous system. Cipla has always been at the forefront of access to medicines. In the early days, the company supplied life-saving drugs to the Indian market at a fraction of the cost of the branded medicines.

Cipla was the first among Indian Pharma Companies to manufacture and sell penicillin in India. Over the years, the company has continued to provide affordable medicines to patients across the world. In 2001, Cipla was the first company to sell antiretroviral drugs in Africa at a price that was one-tenth of the price charged by the leading brand.

This helped bring treatment within the reach of millions of people living with HIV/AIDS. Cipla is a research-based company and has over 1,500 scientists working in R&D. The company has over 200 products in the pipeline and launches 10-15 new products every year. Cipla has over 50 manufacturing facilities across India, Africa, Europe, and the Americas.

Cipla NSE Share Price

Here is the Cipla Pharma Share price from NSE. The LTP as on 26 April 2023 is Rs. 913. Follow the below Cipla share Price NSE chart on a Monthly time frame.

Cipla Company Financials & Fundamentals

Here are the key fundamentals of Cipla along with a market cap, turnover, sales, profit, and more. Cipla contributes a second massive after Sun Pharma’s weightage of a whopping 14.17% in the Nifty Pharma Stock Weightage.

• MARKET CAP: ₹ 90,308.84 Cr.
• COMPANY VALUE: ₹ 88,880.81 Cr.
• P/E: 35.33
• DIVIDEND YIELD: 0.44 %
• PROMOTER HOLDING: 33.41 %
• SALES GROWTH: 15.83%
• ROE: 12.70 %
• ROCE: 16.84%

Cipla Products List

Cipla is known to manufacture products broadly in the following categories:

• Asthma
• Respiratory
• Pediatric Asthma
• COPD
• Nebulization
• HIV/AIDS
• Oncology
• Cipla Generics
• Our Offerings
• OTC – Cipla Health
• Cipla Diagnostics
• API

Here is the complete Cipla Products List:

Cipla Awards and CSR

The company has a strong focus on quality and compliance and has been accredited by leading global agencies such as the US FDA, UK MHRA, and WHO. Cipla is committed to sustainable development and has been recognized as a leading corporate citizen in India.

The company has been honored with the coveted ‘Golden Peacock Award for Corporate Social Responsibility. Cipla Foundation, the CSR arm of the company, works on health and education initiatives in rural India. Cipla also supports the treatment of underprivileged cancer patients through its ‘Cipla Cancer Care’ program.

End Words on Cipla Products List

In conclusion, Cipla is a company that is committed to providing affordable, quality medicines to people around the world. The company has a long history of innovation and social responsibility and is a trusted partner of the Indian government in providing affordable medicines to the country’s citizens. Cipla is also a leading manufacturer of generic medicines and is constantly expanding its product portfolio to meet the needs of patients and doctors alike.